This Week in Hematology — May 28, 2026

Welcome to This Week in Hematology. This week we're covering seven notable papers spanning measurable residual disease in AML, the fundamental biology of stem cell aging, and clinical challenges in treating hematologic disorders. Let's dive in.

Our first theme is the evolving landscape of measurable residual disease, or MRD, in acute myeloid leukemia. We know that detecting MRD before an allogeneic stem cell transplant is crucial for risk stratification. But two papers this week in Haematologica highlight both the current challenges and a potential path forward.

The first paper, from Tettero and colleagues, reports on a large, real-world observational study from the CIBMTR registry [1]. They examined outcomes for over 2,500 AML patients in their first remission who underwent transplant. Pre-transplant MRD was detected by multiparameter flow cytometry in about 11% of patients. As expected, MRD positivity was bad news. It was associated with a roughly 30% higher risk of death and a 40% higher risk of relapse. The one-year cumulative incidence of relapse was 35% in the MRD-positive group versus 25% in the MRD-negative group. However, the study uncovered a major caveat. The prognostic impact of an MRD test varied substantially across the 12 largest transplant centers, underscoring the real-world problem of variability in flow cytometry methods and sensitivity thresholds. Furthermore, a 25% relapse risk even in the MRD-negative group shows that current registry-level testing isn't sensitive enough to provide complete reassurance. The bottom line is that while flow cytometry for MRD is clinically relevant, its reliability is seriously hampered by a lack of standardization.

This brings us to the second paper, from Krauss and colleagues, which presents a potential solution [2]. They developed a cost-efficient and sensitive next-generation sequencing, or NGS, assay for MRD. The assay uses single-molecule molecular inversion probes to target 92 genomic loci in 33 common AML driver genes. They applied this to 93 AML patients in remission before transplant. MRD positivity was defined as a variant allele frequency of 0.5% or higher in any non-CHIP gene. The results were striking. Pre-transplant MRD positivity by this NGS method was a powerful, independent predictor of inferior overall survival, increasing the hazard of death by more than four-and-a-half times. What makes this particularly compelling is the practicality. The authors report library preparation costs of approximately 8 Euros per sample. This affordability could facilitate wide implementation, allowing more patients to benefit from highly sensitive, and importantly, standardized MRD-directed treatment decisions before transplant. Together, these two papers paint a clear picture: the field is grappling with the limitations of non-standardized flow cytometry, and cost-effective, broadly applicable NGS assays may be the key to more reliable risk stratification in AML.

Next, we turn to two landmark papers published in Nature that fundamentally advance our understanding of how human hematopoietic stem cells, or HSCs, age and respond to stress.

The first, by Zeng and colleagues, introduces the concept that HSCs remember previous inflammation [3]. Using xenograft models and single-cell multi-omics, they identified a distinct HSC subset they term 'HSC inflammatory memory', or HSC-iM. After exposure to inflammatory stress, these cells enter a quiescent state with restrained hematopoietic output, retaining a molecular memory of the inflammation. This isn't just a lab curiosity. The researchers found this HSC-iM program enriched in stem cells from patients across a range of conditions, including post-COVID-19 recovery, sickle cell disease, and normal aging. It was also present in individuals with clonal hematopoiesis, where CH driver mutations appeared to blunt the inflammatory memory program, promoting HSC activation. Critically, this pro-inflammatory program was passed down to differentiated immune progeny. And in a large population cohort, enrichment of this HSC-iM signature in circulating blood cells was associated with a heightened risk score for all-cause mortality. This work identifies a new, clinically relevant HSC state that helps explain how a lifetime of inflammatory insults contributes to health and disease.

In a complementary study, Gupta and colleagues investigated the mechanism behind another hallmark of aging: the accumulation of mitochondrial DNA mutations in blood [4]. The classic theory has been that these mutations result from oxidative damage over a lifetime. This paper challenges that dogma. Analyzing whole-genome sequences from nearly 750,000 individuals, they found that the mutational spectrum of these variants is more consistent with replication errors than with oxidative lesions. So why do they accumulate with age? The key insight is clonal expansion. The study found strong genetic links between a high burden of mitochondrial DNA mutations and germline variants in genes like TERT, which are known drivers of clonal hematopoiesis. The authors propose a new model: these 'cryptic' mitochondrial mutations arise randomly from replication errors at undetectable levels. They only become apparent in bulk blood samples when a hematopoietic stem cell clone expands, bringing all of its unique mitochondrial variants along for the ride. This elegantly reframes the accumulation of mitochondrial DNA mutations not as a cause of aging, but as a highly sensitive, blood-based biomarker of somatic mosaicism due to clonal hematopoiesis. It mechanistically unifies three prominent signatures of aging: common germline risk variants, clonal hematopoiesis, and the accrual of mitochondrial DNA mutations.

Our final section covers a diverse set of clinical challenges, from managing treatment complications to understanding rare genetic drivers.

First, a practical paper from Haematologica by Lucchini and colleagues addresses autoimmune cytopenias, or AICs, that occur after alemtuzumab induction for renal transplantation [5]. In a single-center retrospective analysis of 40 patients, they found that immune thrombocytopenia, autoimmune hemolytic anemia, or Evans syndrome are significant complications. The incidence peaked at two time points: 18 and 36 months post-alemtuzumab, coinciding with the period of immune reconstitution. For ITP, treatments like rituximab and thrombopoietin receptor agonists, or TPO-RAs, were highly effective. In fact, rituximab achieved a higher response rate, at over 90%, and a longer duration of response than is typical for primary ITP. Similarly, half the patients on TPO-RAs were able to stop the drug and maintain remission. However, management was complicated by high rates of adverse events, particularly infections, which affected over 60% of patients, and thrombosis. The clinical takeaway is to be aware of this complication, but also that standard therapies are very effective. Proactive supportive care with antimicrobials and careful management of anticoagulation is essential.

Next, shifting to malignant hematology, a paper in the British Journal of Haematology from Wang and colleagues sheds new light on the genetics of B-cell acute lymphoblastic leukemia [6]. Specifically, they focused on rearrangements of the PAX5 gene, a critical driver in B-ALL. They identified a novel in-frame fusion, PAX5::GSE1, and showed that it promotes cell proliferation. By analyzing a large cohort of 330 patients with PAX5-rearranged B-ALL, they found a remarkable diversity, with 76 different fusion partner genes. Despite this diversity, transcriptomic analysis revealed a convergent molecular signature. PAX5-rearranged leukemias consistently showed dysregulation of the RB1 and p53 tumor suppressor pathways and overexpression of NPM1. This work helps clarify the core mechanisms of this B-ALL subtype and, by identifying a common downstream signature, highlights potential therapeutic vulnerabilities for future drug development.

Finally, we have a paper from JAMA that, while from the general medicine literature, has important implications for managing our often-complex hematology patients [7]. Wang and colleagues performed a massive network meta-analysis of over 700 randomized trials to assess adverse effects and treatment discontinuation for all major classes of blood pressure-lowering drugs. The primary outcome was stopping the drug due to side effects. Compared to placebo, calcium channel blockers and combinations like ACE inhibitors plus calcium channel blockers or beta-blockers plus thiazides all significantly increased the odds of treatment discontinuation. The standout finding, however, was about angiotensin II receptor blockers, or ARBs. ARB monotherapy and ARBs combined with calcium channel blockers were the only regimens that had significantly *fewer* treatment discontinuations due to adverse events than placebo. This suggests a net symptomatic improvement for patients taking them. For clinicians managing hypertension in patients who may already be dealing with treatment side effects from their primary hematologic therapy, this provides a clear, evidence-based rationale for preferring ARB-based regimens to improve adherence and tolerability.

Editor's Pick If you only have time for one paper this week, make it the Nature study by Gupta and colleagues on the mechanism of mitochondrial DNA mutation accumulation [4]. It elegantly reframes these mutations not as a primary driver of aging from oxidative damage, but as a sensitive biomarker of clonal hematopoiesis, unifying several key concepts in hematopoietic aging.

Clinical Bottom Line Here are the key takeaways from this week in Hematology.

First, in AML, pre-transplant MRD testing by flow cytometry is prognostically useful but hampered by real-world variability. New, affordable NGS-based assays may provide a more standardized and sensitive alternative for risk stratification [1, 2].

Second, our understanding of hematopoietic aging is deepening. Stem cells can retain an 'inflammatory memory' linked to higher mortality risk, and the accumulation of mitochondrial DNA mutations appears to be a sensitive marker of clonal hematopoiesis, not a direct result of oxidative damage [3, 4].

Third, for autoimmune cytopenias following alemtuzumab induction, be aware that rituximab and TPO-RAs are highly effective, but that these patients are at high risk for both infection and thrombosis, requiring vigilant supportive care [5].

And finally, when managing hypertension, a large network meta-analysis found that ARB-based regimens were the only class associated with fewer treatment discontinuations than placebo, suggesting superior tolerability and a good first choice for improving adherence [7].

That's your roundup for This Week in Hematology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.